Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma Group (MREO) Net Cash Flow: 2023-2025

Historic Net Cash Flow for Mereo BioPharma Group (MREO) over the last 3 years, with Sep 2025 value amounting to -$7.0 million.

  • Mereo BioPharma Group's Net Cash Flow rose 13.61% to -$7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$32.5 million, marking a year-over-year decrease of 312.50%. This contributed to the annual value of $12.6 million for FY2024, which is 192.90% up from last year.
  • Latest data reveals that Mereo BioPharma Group reported Net Cash Flow of -$7.0 million as of Q3 2025, which was up 9.97% from -$7.8 million recorded in Q2 2025.
  • In the past 5 years, Mereo BioPharma Group's Net Cash Flow ranged from a high of $38.9 million in Q2 2024 and a low of -$9.7 million during Q1 2023.
  • Over the past 3 years, Mereo BioPharma Group's median Net Cash Flow value was -$7.8 million (recorded in 2025), while the average stood at -$2.2 million.
  • Within the past 5 years, the most significant YoY rise in Mereo BioPharma Group's Net Cash Flow was 601.39% (2024), while the steepest drop was 176.79% (2024).
  • Quarterly analysis of 3 years shows Mereo BioPharma Group's Net Cash Flow stood at -$6.8 million in 2023, then plummeted by 39.34% to -$9.5 million in 2024, then increased by 13.61% to -$7.0 million in 2025.
  • Its Net Cash Flow was -$7.0 million in Q3 2025, compared to -$7.8 million in Q2 2025 and -$8.2 million in Q1 2025.